☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Vildagliptin delayed

The launched of vildagliptin (Glavus®) has been delayed by a safety update on liver enzyme elevations according to PharmaTimes.

The article states that liver enzyme elevations were less frequent in patients taking 50mg each day or 50mg twice daily compared to those taking 100mg daily. This finding has raised safety concerns and may impact on the use of this drug as a true once-daily medication.

Action: The gliptins are new agents and their place in therapy is where other agents have failed or are not tolerated. Previous recommendations are unchanged.

Share 'Vildagliptin delayed' by emailShare 'Vildagliptin delayed' on FacebookShare 'Vildagliptin delayed' on TwitterShare 'Vildagliptin delayed' on LinkedInShare 'Vildagliptin delayed' on reddit

atomic-wealth

One Comment to “Vildagliptin delayed”

  1. [...] This provides some reassurance with respect to the liver enzyme elevations that delayed the drugs launch however patients with clinically significant liver disease or abnormal liver enzyme results at [...]

    Pingback by Prescribing Advice for GPs » Longer term gliptin data — May 22, 2009 #
    Reply

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.

governor
governor
governor
governor